<ul><li>Belgian BioTech startup Quidditas secured €2.62 million funding to advance its recombination-based genome editing technology.</li><li>The funding includes a €900k capital increase led by iXLife Capital and a €1.72 million grant from the Ministry of Research in Wallonia.</li><li>Quidditas aims to develop precise solutions for genetic disorders and acknowledges the support for enhancing healthcare through genomic medicine.</li><li>The company's genome editing platform offers applications in gene therapy, protein bioproduction, and regenerative medicine, setting a goal to revolutionize the sector.</li></ul>

Belgian BioTech startup Quidditas raises €2.62 million for genome editing technology

Discover more